Author:
Tamura Ryota,Toda Masahiro
Reference80 articles.
1. Abe T, Terada K, Wakimoto H, Inoue R, Tyminski E, Bookstein R, Basilion JP, Chiocca EAPTEN. Decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Research. 2003;63:2300-2305
2. Aghi M, Martuza RL. Oncolytic viral therapies—The clinical experience. Oncogene. 2005;24:7802-7816
3. Ahmed AU, Alexiades NG, Lesniak MS. The use of neural stem cells in cancer gene therapy: Predicting the path to the clinic. Current Opinion in Molecular Therapeutics. 2010;12:546-552
4. Ahmed AU, Rolle CE, Tyler MA, Han Y, Sengupta S, Wainwright DA, Balyasnikova IV, Ulasov IV, Lesniak MS. Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Molecular Therapy. 2010;18:1846-1856
5. Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F, Balyasnikova IV, Ulasov IY, Aboody KS, Lesniak MS. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Molecular Therapy. 2011;19:1714-1726